List of new drugs for expanded indication in relation to the COVID-19 pandemic
Under the interim order, the Minister of Health may permit the sale of a previously approved new drug for a new indication (use) that has not yet been authorized in Canada. The manufacturer does not need to apply for this new use.
The new use must be associated with the urgent public health need as a result of COVID-19. The Minister must have evidence that the benefits of this expanded use outweigh the risks.
The requirements for this list are outlined in section 15 of the Interim Order.
The following table contains the most current list of new drugs for expanded indication in relation to the COVID-19 pandemic.
Supplementary information pertaining to the expanded indication of each new drug is also published by Health Canada and is linked from each entry.
In the table, the entry for each new drug for expanded use includes the:
- manufacturer
- brand name, proper name or common name
- medicinal ingredient(s), strength, dosage form, and route of administration
- drug identification number (DIN)
- expanded use for COVID-19
Date issued: 2020-09-17
| Item No. | Manufacturer | Brand name, proper name or common name | Medicinal ingredient(s), strength, dosage form, route of administration | DIN | Expanded indication |
|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a |
Page details
- Date modified: